- 2022
- In November,SIMR Biotech received 150 million Chinese Yuan C1 round of financing to accelerate product development and commercialization cooperation
- In June, the first subject administration was completed in the Chinese clinical trial of SR1375
- In May, SR419, a drug candidate with a novel mechanism of action for the treatment of peripheral neuropathic pain, was granted fast track designation (FTD) by the U.S. Food and Drug Administration (
- 2021
- In December, SR419, the Company's first innovative drug to enter the clinical stage, was approved by the US Food and Drug Administration (FDA) for its international multi-center Phase II clinical st
- In October, it completed the B+ round financing of nearly RMB200 million led by Zhang Jiang Haocheng and Zhang Jiang Haoheng
- In October, the second drug candidate, SR1375, successfully completed its first dose group administration in Australia.
- In July, the China IND application for SR419, SIMR Biotech's first analgesic candidate, was approved by the implied license
- In February,SIMR Biotech Advisory Board (SAB) was established with the appointment of four internationally well-knowed pain experts.
- 2020
- September-The first patient successfully dosed with the candidate drug SR419
- 2019
- July-SIMR initiated the first-in-human study of candidate drug SR419 for peripheral neuropathic pain
- 2018
- November - Received over 100 million RMB for A round of financing
- May - The SPF animal facilities passed the on-site audit
- 2017
- May - SIMR received financial support from the Smart Manufacturing Industry in Lingang
- 2016
- November - Received over ten millions RMB for Pre-A round of financing
- SIMR was granted as one of the "50 Best Startups with Highest Investment Potential in Shanghai"
- 2015
- June-SIMR was supported by the 2015 Shanghai SME Innovation Fund
- 2014
- March 6 - Shanghai SIMR Biotechnology Co., Ltd. was established in Shanghai
